BMJ  2003;327:845-846 (11 October), doi:10.1136/bmj.327.7419.845

Primary care

Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users

Beverley Lawton, senior research fellow1, Sally Rose, research fellow1, Deborah McLeod, research director1, Anthony Dowell, professor of general practice1

1 Department of General Practice, Wellington School of Medicine and Health Sciences, PO Box 7343, Wellington South, New Zealand

Correspondence to: B Lawton bevlawton@wnmeds.ac.nz

The first 150 words of the full text of this article appear below.

Introduction

In 2002 the Women's Health Initiative reported the results of a study on the effects of combined oestrogen plus progestogen on healthy postmenopausal women. They found increased rates of breast cancer, coronary heart disease, stroke, and venous thromboembolism and decreased rates of hip fracture and colorectal disease but no "global" benefit. They concluded that combined oestrogen and progestogen is not suitable for the prevention of chronic diseases.1 The subsequent extensive media coverage came at a time when the prevalence,2 3 duration,2 4 and use of hormone replacement therapy (HRT) for the prevention of chronic disease had been increasing.2 4 After the report, government regulatory authorities issued advice to health professionals and women, and guidelines relating to the postmenopausal use of hormone replacement therapy were updated.5 We examined changes in HRT use since the publication of the report.

Participants, methods, and results

Between January 2000 and November 2002, 3500 women were screened from 23 general practices in four . . . [Full text of this article]

Comments


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women
Madge R Vickers, Alastair H MacLennan, Beverley Lawton, Deborah Ford, Jeannett Martin, Sarah K Meredith, Bianca L DeStavola, Sally Rose, Anthony Dowell, Helen C Wilkes, Janet H Darbyshire, Tom W Meade WISDOM group
BMJ 2007 335: 239. [Abstract] [Full Text] [PDF]

Trial results have dramatically reduced HRT use
BMJ 2003 327: 0. [Full Text]

This article has been cited by other articles:

  • Ballard, K. D., Elston, M. A., Gabe, J. (2009). Private and Public Ageing in the UK: The Transition through the Menopause. Current Sociology 57: 269-290 [Abstract]  
  • Li, M., Chapman, S., Agho, K., Eastman, C. J. (2008). Can even minimal news coverage influence consumer health-related behaviour? A case study of iodized salt sales, Australia. Health Educ Res 23: 543-548 [Abstract] [Full text]  
  • Vickers, M. R, MacLennan, A. H, Lawton, B., Ford, D., Martin, J., Meredith, S. K, DeStavola, B. L, Rose, S., Dowell, A., Wilkes, H. C, Darbyshire, J. H, Meade, T. W, WISDOM group, (2007). Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335: 239-239 [Abstract] [Full text]  
  • Clegg Smith, K., Cho, J., Gielen, A., Vernick, J. S (2007). Newspaper coverage of residential fires: an opportunity for prevention communication. Inj. Prev. 13: 110-114 [Abstract] [Full text]  
  • Rice, S., Whitehead, S. A (2006). Phytoestrogens and breast cancer -promoters or protectors?. Endocr Relat Cancer 13: 995-1015 [Abstract] [Full text]  
  • Mishra, G., Kok, H., Ecob, R., Cooper, R., Hardy, R., Kuh, D. (2006). Cessation of Hormone Replacement Therapy After Reports of Adverse Findings From Randomized Controlled Trials: Evidence From a British Birth Cohort. AJPH 96: 1219-1225 [Abstract] [Full text]  
  • Whelan, A. M., Jurgens, T. M, Bowles, S. K (2006). Natural Health Products in the Prevention and Treatment of Osteoporosis: Systematic Review of Randomized Controlled Trials. The Annals of Pharmacotherapy 40: 836-849 [Abstract] [Full text]  
  • Wei, F., Miglioretti, D. L., Connelly, M. T., Andrade, S. E., Newton, K. M., Hartsfield, C. L., Chan, K. A., Buist, D. S. M. (2005). Changes in Women's Use of Hormones After the Women's Health Initiative Estrogen and Progestin Trial by Race, Education, and Income. J Natl Cancer Inst Monogr 2005: 106-112 [Abstract] [Full text]  
  • Ness, J., Aronow, W. S., Newkirk, E., McDanel, D. (2005). Use of Hormone Replacement Therapy by Postmenopausal Women After Publication of the Women's Health Initiative Trial. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60: 460-462 [Abstract] [Full text]  
  • Majumdar, S. R., Almasi, E. A., Stafford, R. S. (2004). Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women's Health Initiative. JAMA 292: 1983-1988 [Abstract] [Full text]  
  • Schwartz, L. M., Woloshin, S. (2004). The Media Matter: A Call for Straightforward Medical Reporting. ANN INTERN MED 140: 226-228 [Full text]  

Rapid Responses:

Read all Rapid Responses

reason
Jo Ann Rosenfeld
bmj.com, 13 Oct 2003 [Full text]
Back to the Dark Ages
PeterR Bradley
bmj.com, 16 Oct 2003 [Full text]
Changes in Italy after the WHI study: the fishing out of tibolone
Anna Maria Marata, et al.
bmj.com, 24 Oct 2003 [Full text]
“It’s an overestimate”
Nicholas Collins, et al.
bmj.com, 13 Nov 2003 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ